BioArctic Partner Eisai to Present New Lecanemab Data at AAIC 2026 — BioArctic AB

Event summary

Eisai will present new clinical and real-world evidence on lecanemab (Leqembi®) at AAIC 2026, including data on subcutaneous formulation, long-term use, and at-home administration.
BioArctic to participate in a plenary session discussing clinical progression strategies for cognitive impairment related to α-synuclein pathology.
Key presentations include LEADER study results evaluating real-world lecanemab use three years post-approval in diverse US clinical settings.
Phase 3 AHEAD 3-45 study updates on preclinical Alzheimer's disease will highlight progress, including participant retention and engagement.

The big picture

BioArctic's partner Eisai is set to present comprehensive data on lecanemab at AAIC 2026, highlighting the drug's evolving role in Alzheimer's treatment. The focus on subcutaneous formulations and real-world evidence reflects a strategic shift towards more accessible and patient-friendly administration methods. This aligns with broader industry trends toward personalized and decentralized healthcare solutions, particularly in neurodegenerative disease management.

What we're watching

Regulatory Progress: Whether Eisai's supplemental Biologics License Application for subcutaneous lecanemab receives FDA approval by the extended PDUFA date of August 24, 2026.
Market Expansion: The pace at which lecanemab gains regulatory approval in additional countries and regions, particularly given its current approval in 53 countries and under review in 6 more.
Clinical Efficacy: How the real-world evidence from diverse clinical settings impacts lecanemab's adoption and long-term use across different patient groups.